Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators.

N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3.

2.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

PMID:
19145003
3.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Heerspink HJ, Persson F, Brenner BM, Chaturvedi N, Brunel P, McMurray JJ, Desai AS, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):309-17. doi: 10.1016/S2213-8587(15)00469-6. Epub 2016 Jan 14.

PMID:
26774608
4.

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators.

N Engl J Med. 2016 Apr 21;374(16):1521-32. doi: 10.1056/NEJMoa1514859. Epub 2016 Apr 4.

5.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

6.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Heerspink HJ, Ninomiya T, Persson F, Brenner BM, Brunel P, Chaturvedi N, Desai AS, Haffner SM, Mcmurray JJ, Solomon SD, Pfeffer MA, Parving HH, de Zeeuw D.

Diabetes Obes Metab. 2016 Feb;18(2):169-77. doi: 10.1111/dom.12600. Epub 2016 Jan 13.

PMID:
26511599
7.

Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators.

JAMA. 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: JAMA. 2013 Apr 10;309(14):1461.

PMID:
23478743
8.

Blood pressure lowering efficacy of renin inhibitors for primary hypertension.

Musini VM, Lawrence KA, Fortin PM, Bassett K, Wright JM.

Cochrane Database Syst Rev. 2017 Apr 5;4:CD007066. doi: 10.1002/14651858.CD007066.pub3. Review.

PMID:
28379619
9.

Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.

Uzu T, Araki SI, Kashiwagi A, Haneda M, Koya D, Yokoyama H, Kida Y, Ikebuchi M, Nakamura T, Nishimura M, Takahara N, Obata T, Omichi N, Sakamoto K, Shingu R, Taki H, Nagai Y, Tokuda H, Kitada M, Misawa M, Nishiyama A, Kobori H, Maegawa H; Shiga Committee for Preventing Diabetic Nephropathy.

PLoS One. 2016 Dec 29;11(12):e0164936. doi: 10.1371/journal.pone.0164936. eCollection 2016.

10.

No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

Gilbert CJ, Gomes T, Mamdani MM, Hellings C, Yao Z, Garg AX, Wald R, Harel Z, Juurlink DN.

Can J Cardiol. 2013 May;29(5):586-91. doi: 10.1016/j.cjca.2013.02.015. Epub 2013 Mar 29.

11.

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.

Hypertens Res. 2012 Aug;35(8):874-81. doi: 10.1038/hr.2012.45. Epub 2012 May 17.

PMID:
22592665
12.

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J; ATMOSPHERE Investigators.

Eur J Heart Fail. 2011 Jan;13(1):107-14. doi: 10.1093/eurjhf/hfq212.

13.

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P.

Curr Drug Saf. 2012 Feb;7(1):76-85. Review.

PMID:
22663961
14.

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.

Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678. Epub 2013 Nov 4.

PMID:
24191305
15.

What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?

de la Sierra A, Salazar J.

Adv Ther. 2011 Sep;28(9):716-27. doi: 10.1007/s12325-011-0049-6. Epub 2011 Jul 29. Review.

PMID:
21809181
16.

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.

Smink PA, Hoekman J, Grobbee DE, Eijkemans MJ, Parving HH, Persson F, Ibsen H, Lindholm L, Wachtell K, de Zeeuw D, Heerspink HJ.

Eur J Prev Cardiol. 2014 Apr;21(4):434-41. doi: 10.1177/2047487313481754. Epub 2013 Mar 6.

PMID:
23467676
17.

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.

Hypertension. 2007 Feb;49(2):276-84. Epub 2006 Dec 11.

18.

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators.

J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):387-93. doi: 10.1177/1470320311434818. Epub 2012 Feb 14.

PMID:
22333485
19.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
20.

Aliskiren in type 2 diabetes and cardiorenal end points.

Du X, Chen Z, Pan B.

N Engl J Med. 2013 Mar 14;368(11):1065. doi: 10.1056/NEJMc1300257#SA2. No abstract available.

PMID:
23484841

Supplemental Content

Support Center